Many of the motor symptoms of Parkinson disease (PD) can be preceded, sometimes for
several years, by non-motor symptoms that include hyposmia, sleep disorders, depression …

Involuntary movements, or dyskinesia, represent a debilitating complication of levodopa (L-
dopa) therapy for Parkinson's disease (PD). L-dopa-induced dyskinesia (LID) are ultimately …

Background: Non‐motor symptoms are detrimental to health‐related quality of life (HRQoL)
of Parkinson's disease patients. In this study, the Non‐Motor Symptoms Scale (NMSS) was …

Several studies, including work from the Parkinson's disease (PD) non-motor group and
others, have established that the non-motor symptoms of PD are common, occur across all …

Non-motor symptoms (NMS) of Parkinson's disease remain the most under-appreciated and
under-researched when taken as a whole. Data is emerging that it is the “totaL” burden of …

Introduction This registry evaluated the 24-month safety and efficacy of levodopa-carbidopa
intestinal gel (LCIG) treatment in advanced Parkinson's disease (PD) patients under routine …

Parkinson's disease (PD) is a neurodegenerative illness and has a common onset between
the ages of 55 and 65 years. There is progressive development of both motor and non-motor …

In a multinational, double‐blind, placebo‐controlled trial (NCT00474058), 287 subjects with
Parkinson's disease (PD) and unsatisfactory early‐morning motor symptom control were …

Motor complications in Parkinson's disease (PD) are associated with long‐term oral
levodopa treatment and linked to pulsatile dopaminergic stimulation. l‐dopa‐carbidopa …

Differences in the expression of non-motor symptoms (NMS) by Parkinson's disease (PD)
patients may have important implications for their management and prognosis. Gender is a …